AUTHOR’S CORRECTION

A Double-Blind, Adjuvant-Controlled Trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai Subjects with CD4-Cell Counts of >300


Faculty of Science and Department of Biostatistics, Faculty of Public Health, Mahidol University, Vajira Hospital, Bangkok, Metropolitan Authority, and Pramongkutklao College of Medicine, Bangkok, Khon Kaen University Hospital, Khon Kaen, Songklanakarindh University, Songkla, and Chiang Mai University, Chiang Mai, Thailand, and The Immune Response Corporation, Carlsbad, California

Volume 7, no. 5, p. 728–733, 2000. The commercial affiliation, equity interests, and patent-licensing arrangement of Dr. Churdboonchart were not disclosed in the manuscript submittal letter. Dr. Churdboonchart was associated with the Trinity Medical Group Co., Ltd., which was formed to sponsor the clinical trial of Remune in Thailand through a collaborative and license agreement with the Immune Response Corporation, the maker of Remune.